Literature DB >> 7561214

Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs.

D F Bratcher1, N Bourne, F J Bravo, M R Schleiss, M Slaoui, M G Myers, D I Bernstein.   

Abstract

Cytomegalovirus (CMV) is the most common congenital viral infection, but little is known about the protective immune mechanisms. The guinea pig (gp) model of congenital CMV was used to evaluate the effects of passive antibody given to pregnant dams on pup survival. Dams received three doses of high-titer gpCMV or control antibody on days -3, -1, and +7, or +1, +3, and +7, in relation to gpCMV challenge. gpCMV was inoculated in the late second to early third trimester at three different doses. Compared with controls, gpCMV antibody begun before gpCMV challenge significantly increased pup survival from 14% to 52%, 21% to 84%, and 51% to 77%, respectively, for the three challenge doses. gpCMV antibody started after viral challenge increased pup survival after only the lowest challenge dose (51% to 81%). Antibody did not protect against CMV infection of the pups. CMV antibody appeared to improve survival in congenital CMV infection but did not affect vertical transmission.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561214     DOI: 10.1093/infdis/172.4.944

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  30 in total

1.  Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.

Authors:  Fernando J Bravo; David I Bernstein; James R Beadle; Karl Y Hostetler; Rhonda D Cardin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

2.  Molecular characterization of the guinea pig cytomegalovirus UL83 (pp65) protein homolog.

Authors:  M R Schleiss; A McGregor; N J Jensen; G Erdem; L Aktan
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

3.  Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties.

Authors:  Irena Slavuljica; Andreas Busche; Marina Babić; Maja Mitrović; Iva Gašparović; Durđica Cekinović; Elitza Markova Car; Ester Pernjak Pugel; Ana Ciković; Vanda Juranić Lisnić; William J Britt; Ulrich Koszinowski; Martin Messerle; Astrid Krmpotić; Stipan Jonjić
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 4.  The tiers and dimensions of evasion of the type I interferon response by human cytomegalovirus.

Authors:  Lisi Amsler; Marieke Verweij; Victor R DeFilippis
Journal:  J Mol Biol       Date:  2013-09-05       Impact factor: 5.469

Review 5.  Cytomegalovirus antivirals and development of improved animal models.

Authors:  Alistair McGregor; K Yeon Choi
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-09-01       Impact factor: 4.481

6.  Identification and characterization of the guinea-pig cytomegalovirus glycoprotein H gene.

Authors:  R C Brady; M R Schleiss
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 7.  Animal Models of Congenital Cytomegalovirus Transmission: Implications for Vaccine Development.

Authors:  Hunter K Roark; Jennifer A Jenks; Sallie R Permar; Mark R Schleiss
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

8.  Cytomegalovirus infection in pregnancy: should all women be screened?

Authors:  Amanda Carlson; Errol R Norwitz; Robert J Stiller
Journal:  Rev Obstet Gynecol       Date:  2010

9.  Repair of a Mutation Disrupting the Guinea Pig Cytomegalovirus Pentameric Complex Acquired during Fibroblast Passage Restores Pathogenesis in Immune-Suppressed Guinea Pigs and in the Context of Congenital Infection.

Authors:  Michael A McVoy; Jian Ben Wang; Dirk P Dittmer; Craig J Bierle; Elizabeth C Swanson; Claudia Fernández-Alarcón; Nelmary Hernandez-Alvarado; Jason C Zabeli; Mark R Schleiss
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

10.  Prevention of maternal cytomegalovirus infection: current status and future prospects.

Authors:  Jessica L Nyholm; Mark R Schleiss
Journal:  Int J Womens Health       Date:  2010-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.